VERAPAMIL HYDROCHLORIDE- verapamil hydrochloride injection, solution

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

유효 성분:

VERAPAMIL HYDROCHLORIDE (UNII: V3888OEY5R) (VERAPAMIL - UNII:CJ0O37KU29)

제공처:

Cardinal Health

INN (국제 이름):

VERAPAMIL HYDROCHLORIDE

구성:

VERAPAMIL HYDROCHLORIDE 2.5 mg in 1 mL

관리 경로:

INTRAVENOUS

처방전 유형:

PRESCRIPTION DRUG

치료 징후:

Verapamil Hydrochloride Injection, USP is indicated for the following: • Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong- Levine [L-G-L] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. • Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White (W-P-W) and Lown-Ganong-Levine (L-G-L) syndromes). In controlled studies in the United States, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutte

제품 요약:

Verapamil Hydrochloride Injection, USP 2.5 mg/mL is supplied in single-dose containers as follows: NDC No. Container Volume Total Content 0409-4011-01 Ampul 2 mL 5 mg 0409-9633-05 ANSYR™ Plastic Syringe 4 mL 10 mg 0409-1144-01 Fliptop Vial 2 mL (5 pack carton) 5 mg 0409-1144-02 Fliptop Vial 4 mL 10 mg 0409-1144-05 Fliptop Vial 2 mL (25 pack tray) 5 mg Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from light by retaining in package until ready to use. Revised: March, 2010 Printed in USA                            EN-2463 Hospira, Inc., Lake Forest, IL 60045 USA Cardinal Health Zanesville, OH 43701 IA6892 0612

승인 상태:

Abbreviated New Drug Application

제품 특성 요약

VERAPAMIL HYDROCHLORIDE- VERAPAMIL HYDROCHLORIDE INJECTION, SOLUTION
CARDINAL HEALTH
----------
VERAPAMIL
HYDROCHLORIDE INJECTION, USP
ANSYR™ PLASTIC SYRINGE
AMPUL
FLIPTOP VIAL
Protect from light.
Rx only
DESCRIPTION
Verapamil hydrochloride is a calcium antagonist or slow-channel
inhibitor. Verapamil Hydrochloride
Injection, USP is a sterile, nonpyrogenic solution containing
verapamil hydrochloride 2.5 mg/mL and
sodium chloride 8.5 mg/mL in water for injection. The solution
contains no bacteriostat or antimicrobial
agent and is intended for single-dose intravenous administration. May
contain hydrochloric acid for pH
adjustment; pH is 4.9 (4.0 to 6.5).
The chemical name of Verapamil Hydrochloride, USP is
benzeneacetonitrile, α-[3-[{2-(3,4-
dimethoxyphenyl)ethyl} methylamino]
propyl]-3,4-dimethoxy-α-(1-methylethyl) hydrochloride.
Verapamil hydrochloride is a white or practically white crystalline
powder. It is practically odorless
and has a bitter taste. It is soluble in water; freely soluble in
chloroform; sparingly soluble in alcohol;
practically insoluble in ether. It has the following structural
formula:
Molecular weight: 491.07
Molecular formula: C
H N O • HCl
Verapamil hydrochloride is not chemically related to other
antiarrhythmic drugs.
The plastic syringe is molded from a specially formulated
polypropylene. Water permeates from inside
the container at an extremely slow rate which will have an
insignificant effect on solution concentration
over the expected shelf life. Solutions in contact with the plastic
container may leach out certain
chemical components from the plastic in very small amounts; however,
biological testing was
supportive of the safety of the syringe material.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION: Verapamil inhibits the calcium ion (and possibly
sodium ion) influx through
slow channels into conductile and contractile myocardial cells and
vascular smooth muscle cells. The
antiarrhythmic effect of verapamil appears to be due to its effect on
the slow channel in cells of the
cardiac